Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NAGE
BUYNiagen Bioscience, Inc. · Healthcare · United States · $256M · Avg Vol: $2M/d
73
StockRankGet insider-trade alerts
Q
84
V
51
M
32
P/E (TTM)
15.3x
ROE
27.1%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
The ticker NAGE, listed as Niagen Bioscience, Inc. in the healthcare sector, does not correspond to a clearly identifiable publicly traded company. Therefore, a specific and factual company profile cannot be accurately generated at this time.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.0M | 83.6M | 99.6M | 129.4M | 21.6% | 130.4M | 141.4M | 165.1M | 12.9% |
| EPS | -0.24 | -0.07 | 0.11 | 0.22 | 100.0% | 0.22 | 0.24 | 0.31 | 18.3% |
| Shares | 74.6M | 75.0M | 77.3M | 79.7M | +6.9% | 79.6M | — | — | — |
| Debt | 4.3M | 3.3M | 2.7M | 2.8M | -12.9% | 2.6M | — | — | — |
| Equity | 28.7M | 28.5M | 46.1M | 76.5M | 38.7% | — | — | — | — |
| Op CF | -15.1M | 7.1M | 12.1M | 13.5M | 37.7% | 4.4M | — | — | — |
| Inv CF | -0.3M | -0.1M | -0.1M | -0.3M | — | — | — | — | — |
| Fin CF | 7.7M | -90.0K | 5.4M | 6.9M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-6.4%
SMA 50SMA 200
Close
$3.23
RSI (14)
42.6
52W High
$11.29
From 52W High
0.3%
SCORE BREAKDOWN
Quality
84
ROIC
16.5%88.0
ROE
27.1%92.9
GP/Assets
78.8%96.1
Op. Margin
5.0%56.0
FCF/Assets
12.4%90.7
Piotroski
668.3
Int. Cover
50.0x88.8
D/E Ratio
0.03x75.2
Current Ratio
4.61x68.2
Value
51
P/E (TTM)
15.3x73.0
EV/EBITDA
17.1x36.9
P/FCF
19.4x58.9
P/B
3.3x40.9
P/S
2.1x67.3
Div Yield
—N/A
Momentum
32
52W High %
29%7.1
RS 6M
-54%12.1
SMA 50/200
0.66x6.1
EPS Rev 4W
0.0%62.6
EPS Rev 12W
0.0%56.8
EPS Improve
+45%52.6
Q Growth
25%64.1
FUNDAMENTALS
Market Cap
$256M
P/E (Forward)
10.5x
Gross Margin
64.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NAGE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NAGE | Niagen Bioscience, Inc.(you) | $256M | 73 | BUY |
| AGEN | Agenus Inc. | $249M | 61 | HOLD |
| ABEO | Abeona Therapeutics Inc. | $345M | 59 | HOLD |
| MDXG | MiMedx Group, Inc. | $626M | 76 | BUY |
| ORMP | Oramed Pharmaceuticals Inc. | $165M | 58 | HOLD |
| ICCC | ImmuCell Corporation | $100M | 78 | BUY |
| FENC | Fennec Pharmaceuticals Inc. | $347M | 54 | HOLD |
| ZVRA | Zevra Therapeutics, Inc. | $563M | 82 | STRONG BUY |
| 0JDK.L | Iovance Biotherapeutics, Inc. | $638M | 64 | HOLD |
| SPRO | Spero Therapeutics, Inc. | $69M | 70 | BUY |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%